Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

418 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-24

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis and steatosis in adult patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch

NCT05224037

Chronic Liver Disease Liver Fibrosis Liver Steatoses

COMPLETED NA

Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis

NCT02456766

Fatty Liver Hepatic Steatosis Liver Steatosis

UNKNOWN

FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis

NCT02476695

Liver Fibrosis Cirrhosis Chronic Hepatitis B

COMPLETED

Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis

NCT02575625

Liver Steatosis

UNKNOWN NA

Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients

NCT07242404

MAFLD HEPATITIS B CHRONIC

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical phase: Phase IV investigator-initiated study Study centers planned: Approximately 4 centers in different regions of the USA

Objectives:

1. Primary Objectives To evaluate the consistency of Liver Stiffness Measurement (LSM) and Ultrasound/Controlled Attenuation Parameters (UAP/CAP) between iLivTouch-FT9000 and FibroScan 530 devices.
2. Secondary Objectives

1. To compare the operational features of the two devices, reflected in the success rate of examination and number of effective examinations.
2. To compare LSM obtained from each device with liver stiffness estimated by APRI, FIB-4, and SAFE scores.
3. The number of adverse events, serious events, and percentage of subjects with events will be calculated for AE, SAE, AE of special interest, and AE leading to study withdrawal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Fibrosis Fatty Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iLivTouch then FibroScan

Subjects in the Group "iLivTouch then FibroScan" will be measured using iLivTouch first and then FibroScan based on the randomization result.

iLivTouch

Intervention Type DEVICE

The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.

FibroScan

Intervention Type DEVICE

The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.

FibroScan then iLivTouch

Subjects in the Group "FibroScan then iLivTouch" will be measured using FibroScan first and then iLivTouch based on the randomization result.

iLivTouch

Intervention Type DEVICE

The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.

FibroScan

Intervention Type DEVICE

The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iLivTouch

The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.

Intervention Type DEVICE

FibroScan

The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a. Adults aged above 18 years old who have at least one indication for TE examination determined by the physicians;
* b. Patients who have test results for platelet count, ALT, AST, globulin, HBA1c, and total bilirubin (TBIL) levels within 60 days;
* c. Patients who are willing to participate in the clinical study and can sign ICF.

Exclusion Criteria

* a. Excessive drinking history within 90 days: For women-140 grams of alcohol per week or more; For men-210 grams of alcohol per week or more;
* b. Patients with alanine aminotransferase (ALT) or aspartate aminotransferase AST \>100 U/ml (or 2.5 × upper limit of normal (ULN) and/or total bilirubin (TBIL) \> 1.8 mg/d (or \>1.5 × ULN =1.2 mg/d);
* c. Patients with a history or current evidence of decompensated liver cirrhosis;
* d. Patients with various space-occupying tumors and cysts in the right liver;
* e. Patients with other serious systemically diseases or a history of malignant tumors;
* f. Patients with ascites;
* g. Patients with a non-healing wound on the right upper abdomen at this moment;
* h. Patients with intracavitary implantation of instruments;
* i. Pregnant women (urine pregnancy test should be performed for all women with child-bearing potential during screening);
* j. Any history of organ transplantation and existing functional grafts (except corneal or hair transplantation);
* k. Lack of or limited legal capacity.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No